Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma

  • Technology appraisal guidance
  • TA1145
  • Published: 

Suggested remit: To appraise the clinical and cost effectiveness of Pembrolizumab within its marketing authorisation for treating head and neck cancer.

This page was last updated: